Roche Holding AG (RHHBY)
| Market Cap | 252.53B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 6.40B |
| EPS (ttm) | 2.31 |
| PE Ratio | 15.26 |
| Forward PE | 14.47 |
| Dividend | $10.20 (25.87%) |
| Ex-Dividend Date | Mar 16, 2023 |
| Volume | 2,198,093 |
| Open | 39.20 |
| Previous Close | 38.83 |
| Day's Range | 39.14 - 39.45 |
| 52-Week Range | 37.88 - 53.86 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 337.04 (+754.78%) |
| Earnings Date | n/a |
About RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases,... [Read more]
Financial Performance
In 2021, RHHBY's revenue was 62.80 billion, an increase of 7.68% compared to the previous year's 58.32 billion. Earnings were 14.94 billion, a decrease of -0.88%.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to 28 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price forecast is $337.04, which is an increase of 754.78% from the latest price.
News
New four year data for Roche's Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
Basel, 20th March 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data for Evrysdi® (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) fr...
New Four-Year Data for Genentech's Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi® (risdiplam) in a broad range of peopl...
Roche Annual General Meeting 2023
Basel, 14 March 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the ordinary Annual General Meeting has elected Severin Schwan as the new Chairman of the Board of Directors with 98.32% ...
Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee
Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
FDA committee backs Roche's lymphoma treatment
A U.S. Food and Drug Administration committee voted in favor of Roche Holding AG's Polivy antibody drug targeting untreated diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma ...
FDA Advisory Committee votes in favour of the clinical benefit of Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Basel, 10 March 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 in favour of Polivy® ...
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advi...
David Roche explains how China's shifting growth model will 'disappoint' global markets
David Roche, president of Independent Strategy, discusses the changing dynamics for the Chinese and global economy.
Roche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo
The VENTANA PD-L1 (SP263) Assay helps determine which patients with non-small cell lung cancer (NSCLC) may be eligible for treatment with Libtayo monotherapy1 based on the results of the Phase III EMP...
RHHBY vs. ABBV: Which Stock Is the Better Value Option?
RHHBY vs. ABBV: Which Stock Is the Better Value Option?
Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
Basel, 23 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identif...
[Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares
Basel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Roche Long Term Foundation acquired 540'000 Roche bearer shares at the price determined via an accelerated book bu...
New phase III data show Roche's Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
Basel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema d...
New Phase III Data Show Genentech's Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive new data from two global Phase III studies, BALATON and COMI...
Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics
New agreement expands activities to include a wide-range of companion diagnostics, including tissue and blood-based biomarkers, sequencing and digital pathology. Collaboration builds on commitment to ...
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition
Basel, 7 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the global phase III COMMODORE 2 study, evaluating the efficacy and safety of crovalimab in people wit...
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
Overall we achieved good results, delivered on our numbers and targets: Roche CEO
Severin Schwan discusses the company's full-year earnings and outlook for the business in the year ahead.
Roche profit misses forecasts, sees COVID-19 related sales decline ahead
Roche Holding AG reported sales growth in 2022, but said it expects a decrease in sales for 2023 due to a drop in the sale of Covid-19 products.
[Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche's Corporate Executive Committee
Basel, 2 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Board of Directors has made the following appointments:
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023
European Commission approves label expansion of Roche's Hemlibra to include people with moderate haemophilia A in the EU
Basel, 01 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission approved the expansion of the Hemlibra® (emicizumab) European Union (EU) marketing authorisati...
Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
Jana Care and Roche Diagnostics aim to develop point-of-care blood testing portfolio to address unmet needs for patients at-home and in remote settings. Jana Care's at-home testing platform to be dist...
Roche launches new test to detect fast spreading Omicron sub-variant
Roche has launched a new PCR test to detect a fast-spreading sub-variant of the Omicron variant of Coronavirus, the Swiss drugmaker said on Thursday.